Emerging therapies for small cell lung cancer

Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembrolizumab, atezolizumab, and durvalumab have led to significant improvements in clinical outcome...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of hematology and oncology Vol. 12; no. 1; pp. 47 - 11
Main Authors:	Yang, Sen, Zhang, Zhe, Wang, Qiming
Format:	Journal Article
Language:	English
Published:	London BioMed Central 02.05.2019 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Research Cancer therapies Cancer treatment Carboplatin Care and treatment Chemotherapy Clinical trials Cytotoxicity Drug dosages Hematology Humans Immunotherapy Immunotherapy - methods Ipilimumab Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - pathology Medical prognosis Medicine Medicine & Public Health Metastasis Methods Monoclonal antibodies Neutropenia Oncology Orphan drugs Pembrolizumab Review RNA polymerase Small cell lung cancer Small cell lung carcinoma Small Cell Lung Carcinoma - drug therapy Small Cell Lung Carcinoma - pathology Targeted cancer therapy Targeted therapy China Small cell lung cancer Chemotherapy Targeted therapy Immunotherapy
ISSN:	1756-8722, 1756-8722
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!